1 min
Medically reviewed: • Sources verified:Retatrutide Safety Profile Phase 3 Discontinuations Bmi Correlation
Discover the retatrutide safety profile from Phase 3 trials, including 18.2% discontinuation rates at 12mg dose, strong BMI correlation with lower rates in higher BMI patients, side effects like dysesthesia, and long-term data.
title: "Retatrutide Safety Profile: Phase 3 Discontinuations and BMI Correlation" description: "Discover the retatrutide safety profile from Phase 3 trials, including 18.2% discontinuation rates at 12mg dose, strong BMI correlation with lower rates in higher BMI patients, side effects like dysesthesia, and long-term data." date: "2025-04-21" tags: ["retatrutide", "phase
Sourcing research‑grade retatrutide?
Compare verified research peptide vendors, review COAs, and evaluate pricing with our comprehensive buyer's guide. All materials are intended strictly for in‑vitro laboratory research.
Ready to explore medical weight management?
Consult with US-based telehealth providers to discuss FDA-approved GLP-1 medications and personalized obesity treatment plans.